Researchers are hard at work trying to understand NF more fully and to find treatments to improve the lives of those with NF. Their studies frequently require participation from affected individuals. The "trials" listed here are opportunities for the NF community to assist in these research projects. All research benefits the NF community as a whole; in the case of drugs being tested, there is also the hope and possibility that the NF participant may personally benefit. Drug trials are normally limited to individuals with specific (and usually severe) symptoms.

	ABI program now recruiting NF2 patients who are ABI users/nonusers for an important research study. Posted August 2007
	Phase II Study of Gleevec®/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patients with Plexiform Neurofibromas
	Phase I Study of Lovastatin for Neurocognitive Dysfunction in Children with Neurofibromatosis Type 1 Children with NF1 and history of learning disabilities within an age range of 10 -17 years will be eligible. Posted May 2006
	Study of Neurofibroma Growth in Neurofibromatosis Type 1 Individuals age 20-50 years diagnosed with NF1 may be eligible to participate in this study.  Participants can either be the first member of their family affected or have a family history of the disease. Posted February 2006
	Variation in Gene Expression in Neurofibromatosis Type 1 Eligible participants have a diagnosis of NF1 and are at least 16 years old. Posted February 2006
	Early Identification of Cognitive Deficits in Children with Neurofibromatosis Type 1. We are currently looking for young children with NF1 to participate in a research study at Children's National Medical Center. We are trying to learn more about how the brain works in infants and pre-school children with NF1. Children with NF1 less than 40 months of age will be eligible for participation. Posted January 2006
	NIH research study: Investigation is aimed at identifying some of the genes that may influence the number of neurofibromas a person with NF1 might develop. Adults (19 years of age and over) who have been diagnosed with NF1 may be eligible for this study. Participants need to have an affected parent or sibling (though other family members do not need to participate in the study). Posted December 2005
	Clinical Trials Sponsored by the National Institutes of Health